Author:
Brindisi Marie-Claude,Brondel Laurent,Meillon Sophie,Barthet Sophie,Grall Sylvie,Fenech Claire,Liénard Fabienne,Schlich Pascal,Astruc Karine,Mouillot Thomas,Jacquin-Piques Agnès,Leloup Corinne,Vergès Bruno,Pénicaud Luc
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference36 articles.
1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006
2. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2;Gutzwiller;Am J Physiol,1999
3. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study;Astrup;Lancet,2009
4. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not;Raun;Diabetes,2007
5. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites;Göke;Eur J Neurosci,1995
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献